EMEA-002211-PIP01-17 - paediatric investigation plan

resminostat

Key facts

• Active substance:
  resminostat
• Therapeutic area:
  Oncology
• Decision number:
  P/0376/2017
• PIP number:
  EMEA-002211-PIP01-17
• Pharmaceutical form(s):
  Coated tablet
• Condition(s) / indication(s):
  Treatment of Cutaneous T-Cell Lymphoma
• Route(s) of administration:
  Oral use
• Decision type:
  W: decision granting a waiver in all age groups for all conditions or indications
• Decision date:
  01/12/2017
• Compliance check done:
  No

Decision

P/0376/2017: EMA decision of 1 December 2017 on the granting of a product specific waiver for resminostat (EMEA-002211-PIP01-17)

Reference Number: EMA/711131/2017